Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Nuwellis, Inc. Common Stock

NUWE

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Last trade $4.32
Day change -$0.16 (-3.57%)
Day range $4.08 – $4.57
Volume 12,871
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.42M
Price / earnings
—
Price / book
0.25×
Price / sales
0.27×
EV / sales
-0.65×
EV / EBITDA
0.49×

Profitability

Earnings per share
-$25.43
Return on assets
-102.31%
Return on equity
-139.57%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.99×
Quick ratio
3.4×
Cash ratio
2.77×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.31M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NUWE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.21M$1.97M$2.4M$2.42M$2.22M$1.73M$1.9M$2.32M
Cost of revenue$674K$471K$719K$770K$772K$767K$837K$967K
Gross profit$1.54M$1.5M$1.68M$1.65M$1.45M$958K$1.07M$1.36M
Selling, general and administrative$3.01M$3.73M$4.52M$3.21M$3.54M$3.19M$3.58M$2.91M
Research and development$584K$942K$1.73M$884K$603K$675K$550K$831K
Total operating expenses$3.59M$4.67M$6.25M$4.1M$4.14M$3.86M$4.13M$3.74M
Operating income-$2.05M-$3.17M-$4.57M-$2.44M-$2.7M-$2.91M-$3.06M-$2.39M
Interest expense-$61K-$6.08M$0$0$0-$10.55M$0$0
Income before taxes-$1.97M-$4.83M-$4.54M-$2.42M$468K-$12.55M-$3.01M-$1.47M
Income taxes$0$0$0$0$0$4K$1K$1K
Net income-$1.97M-$4.83M-$4.54M-$2.42M$468K-$12.55M-$3.01M-$1.47M
Net income attributable to common shareholders-$1.97M-$4.83M-$4.54M-$2.42M$468K-$12.55M-$3.01M-$1.47M
EBITDA-$2.02M-$3.13M-$4.53M-$2.41M-$2.65M-$2.86M-$2.99M-$2.3M
Basic earnings per share-$5.81-$239.76-$689.85-$472.44$176.87-$19,207.71-$9,112.95-$6,244.56
Diluted earnings per share-$5.81-$239.76-$689.85-$472.44$176.87-$19,207.71-$9,112.95-$6,244.56

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

Nuwellis announced publication of the ULTRA-Peds Registry study in Pediatric Nephrology, evaluating 91 pediatric patients across seven children's hospitals using the Aquadex SmartFlow System. The study demonstrated 87% patient survival rates and 86.5% procedure completion without interruption, with 62% of patients weighing less than 10 kg. These findings support the company's proposed FDA label expansion for Aquadex from patients weighing 20 kg and above to those weighing 5 kg and above, following a successful pre-submission meeting with the FDA earlier in 2026.

GlobeNewswire Inc.

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Nuwellis announced a co-promotion and distribution agreement with Atrility Medical for the AtriAmp device, an FDA-cleared technology for temporary epicardial pacing. The deal includes an initial six-month pilot across nine Western and five Southeastern states, with a pathway to exclusive U.S. distribution upon successful completion. This strategic partnership allows Nuwellis to expand its pediatric and critical care portfolio without significant additional infrastructure investment.

GlobeNewswire Inc.

Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)

Nuwellis, Inc. (Nasdaq: NUWE) marks five years of supporting the Pediatric Cardiac Critical Care Consortium (PC4) annual conference, collaborating with leading pediatric cardiac institutions to advance fluid management education and awareness. The company's Aquadex SmartFlow system is utilized across major pediatric cardiac centers for managing fluid overload in critically ill children. Incoming CEO Mike McCormick emphasized the company's commitment to pediatric care advancement and fluid management strategies in cardiac ICUs.

Benzinga

Nuwellis Announces Closing of $6.0 Million Registered Public Offering

Nuwellis (NASDAQ: NUWE), a medical technology company focused on cardiorenal conditions, announced the successful closing of a $6.0 million registered public offering. The offering included 1.9 million shares of common stock and pre-funded warrants, with accompanying Series C and D warrants. The public offering price was $0.30 per share with accompanying warrants.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 27, 20261-for-9reverse split
Jun 26, 20261-for-35reverse split
Jul 7, 20251-for-42reverse split
Jun 28, 20241-for-35reverse split
Dec 12, 20221-for-100reverse split
Oct 19, 20201-for-30reverse split
Jan 3, 20191-for-14reverse split
Oct 13, 20171-for-20reverse split